How to legally get Wegovy online in California

Introduction: Navigating the Telehealth Weight Loss Landscape

The rise of GLP-1 medications like Wegovy, Ozempic, and Mounjaro has transformed weight management, offering many people significant results where other approaches have failed. At the same time, telehealth has expanded healthcare access, making weight loss treatment more convenient. But can you actually get these medications through telehealth services? With varying regulations across states, many patients are confused about their options.

The good news: Yes, in most states, you can legally obtain GLP-1 weight loss medications through telehealth consultations. Since these medications are not controlled substances, federal law does not require an in-person visit before prescribing. However, state-specific regulations create a patchwork of rules that affect how and when you can access these treatments remotely.

This comprehensive guide breaks down the telehealth landscape for weight loss medications across the United States, helping you understand what’s possible in your state and what to expect when seeking treatment online.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Understanding Telehealth Prescribing for Weight Loss Medications

What Makes GLP-1s Different From Other Weight Loss Drugs

GLP-1 agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) work differently from traditional weight loss medications:

• They mimic natural hormones that regulate appetite and blood sugar
• They’re administered via injection rather than pills
• They’re not controlled substances (unlike older diet medications like phentermine)
• They require gradual dose escalation and ongoing monitoring

This non-controlled status is critical for telehealth access. Unlike stimulant medications that face strict DEA regulations, GLP-1 medications can generally be prescribed via telehealth without the federal restrictions that apply to controlled substances.

Federal vs. State Regulations

When it comes to telehealth prescribing of weight loss medications, two regulatory layers matter:

Federal regulations: The Ryan Haight Act requires in-person examinations before prescribing controlled substances via telehealth. However, GLP-1 medications are not controlled substances, so this federal restriction doesn’t apply to them. During the COVID-19 pandemic, telehealth rules were relaxed for all prescriptions, and while some emergency provisions for controlled substances are temporary (currently extended through December 31, 2025), non-controlled medications like Wegovy remain fully accessible via telehealth under federal law.

State regulations: Individual states can impose additional requirements beyond federal law. Some states mandate in-person exams before prescribing any medication (including non-controlled drugs) or have specific rules for weight loss treatments. State medical boards also determine which healthcare providers (physicians, nurse practitioners, physician assistants) can prescribe these medications.

State-by-State Telehealth Access to Weight Loss Medications

States with No In-Person Requirements

These states allow complete telehealth access to weight loss medications with no mandatory in-person visits:

• California: Explicitly permits telehealth prescribing; no in-person exam required.
• Connecticut: Permanent telehealth law allows GLP-1 prescribing without in-person visits.
• Florida: No physical exam requirement, though follow-ups every three months are mandated.
• Illinois: Telehealth is well-established with no in-person exam needed.
• New York: Telehealth-friendly state with no in-person requirement for weight loss medications.
• Pennsylvania: No in-person mandate for GLP-1 prescriptions.
• Washington: Pioneering telehealth state with no in-person requirements.

In these states, you can complete your entire weight management journey virtually, from initial consultation to ongoing care, as long as the provider is licensed in your state.

States Requiring Initial In-Person Visits

Some states have laws or medical board policies requiring an in-person initial examination before telehealth prescribing of weight loss medications:

• Arkansas: One of the most restrictive states, requiring first exam in-person.
• Delaware: Initial in-person exam required before telehealth prescribing.
• Georgia: Requires in-person examination prior to telehealth weight loss prescriptions.
• Mississippi: State law requires seeing the patient in-person at least once.
• New Jersey: Requires comprehensive in-person exam plus labs before GLP-1 prescribing.
• North Dakota: Expects an in-person initial evaluation for weight loss treatment.
• South Carolina: Must examine patient in-person first for weight management.
• Texas: In-person exam generally expected prior to telehealth weight loss prescriptions.
• Utah: Initial in-person exam encouraged by state guidelines.
• Virginia: Must perform physical exam and labs initially; follow-up within 30 days required.

In these states, you’ll typically need to visit a provider’s office for your first appointment, but follow-up visits and prescription refills can often be handled via telehealth.

Provider Qualifications and State Authority Differences

The type of healthcare provider you see via telehealth also matters, as states have different rules about who can prescribe these medications:

Physicians (MDs and DOs)

All states allow licensed physicians to prescribe GLP-1 medications via telehealth (subject to the state’s telehealth rules). The physician must be licensed in the state where you are physically located.

Nurse Practitioners (NPs)

NP authority varies significantly by state:

• Full Independent Practice States: In states like Washington, California, New York, and North Dakota, NPs can prescribe GLP-1 medications independently without physician oversight.
• Collaborative Practice States: In states like Texas, Florida, and Pennsylvania, NPs must have a formal agreement or collaboration with a physician to prescribe medications.

Physician Assistants (PAs)

PAs typically require some form of physician supervision in most states, though the specific requirements vary. In all states, properly supervised PAs can prescribe non-controlled substances like GLP-1 medications.

What to Expect From a Legitimate Telehealth Weight Loss Consultation

A reputable telehealth provider like Klarity Health will follow these steps when prescribing weight loss medications:

1. Comprehensive Initial Assessment

• Detailed medical history and current medication review
• Height, weight, and BMI calculation (typically BMI ≥30, or ≥27 with weight-related conditions)
• Discussion of previous weight loss attempts
• Review of potential contraindications (pregnancy, personal/family history of medullary thyroid carcinoma, etc.)
• Evaluation of lifestyle factors

2. Informed Consent and Education

• Explanation of how GLP-1 medications work
• Discussion of potential side effects (GI symptoms, risks of gallstones, etc.)
• Setting realistic expectations about gradual weight loss
• Information on required lifestyle modifications (diet, exercise)

3. Treatment Plan and Monitoring

• Prescription for appropriate starting dose with gradual titration
• Laboratory testing recommendations when needed
• Regular follow-up schedule (typically monthly at first, then every 2-3 months)
• Weight loss tracking and side effect monitoring
• Adjustments to treatment as needed

4. Ongoing Support

• Access to providers for questions between appointments
• Nutritional guidance and behavioral support
• Medication management and dose adjustments
• Long-term planning for maintenance

At Klarity Health, our providers ensure you receive this comprehensive care regardless of your location, working within the framework of your state’s telehealth regulations while providing the same standard of care you’d receive in person.

Red Flags: Avoiding Unsafe Telehealth Providers

Not all telehealth providers are created equal. Be wary of services that:

• Promise guaranteed prescriptions without thorough evaluations
• Offer ‘compounded’ versions of semaglutide (the FDA banned most compounded versions in 2025)
• Don’t schedule regular follow-ups or monitor progress
• Lack transparency about provider credentials or licensure
• Skip discussion of risks, side effects, and alternatives
• Don’t integrate lifestyle recommendations into the treatment plan

A legitimate provider will always conduct a thorough assessment, provide clear information about risks and benefits, and monitor your progress through regular follow-up appointments.

Insurance Coverage and Accessibility

While telehealth has made weight loss treatment more accessible, insurance coverage varies:

• Private Insurance: Many plans now cover GLP-1 medications for obesity, but often with prior authorization requirements
• Medicare: Covers some telehealth visits but has restrictions on covering weight loss medications
• Medicaid: Coverage varies by state, with some states covering both telehealth and GLP-1s
• Self-Pay Options: Many telehealth providers offer transparent cash pricing

At Klarity Health, we work with both insurance and self-pay patients, providing clear pricing information upfront so you can make informed decisions about your care. Our team can help navigate

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid